PolyActiva has announced the first U.S. patient has been enrolled in our Phase 2b clinical trial evaluating PA5108, an investigational new chemical entity, intracameral ocular micro implant, for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension.

PolyActiva has expanded their Executive Team, appointing Wes Brazell as Chief Financial Officer, and Michael Brubaker, PhD, as Chief Scientific Officer. Their appointments come at an important time for the company, following the recent appointment of Jerry St. Peter as Chief Executive Officer, and Vanessa Waddell continuing in her key leadership role as Chief Strategy Officer.

With this bolstered executive team, PolyActiva is poised to scale globally and advance the lead product candidate, PA5108, into late-stage clinical development.